Accounts Payable, Current of Inhibrx, Inc. from 31 Dec 2019 to 31 Mar 2024
- Taxonomy & unit
- us-gaap: USD
- Description
- Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
- Summary
-
Inhibrx, Inc. quarterly Accounts Payable, Current in USD history and change rate from 31 Dec 2019 to 31 Mar 2024.
- Inhibrx, Inc. Accounts Payable, Current for the quarter ending 31 Mar 2024 was $14,792,000, a 36% increase year-over-year.
- Source SEC data
- View on sec.gov
Accounts Payable, Current, Quarterly (USD)
Accounts Payable, Current, YoY Quarterly Change (%)
Inhibrx, Inc. Quarterly Accounts Payable, Current (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q1 2024 | $14,792,000 | +$3,876,000 | +36% | 31 Mar 2024 | 10-Q | 09 May 2024 | 2024 | Q1 |
| Q4 2023 | $10,954,000 | +$2,628,000 | +32% | 31 Dec 2023 | 10-Q | 09 May 2024 | 2024 | Q1 |
| Q3 2023 | $7,858,000 | -$711,000 | -8.3% | 30 Sep 2023 | 10-Q | 09 Nov 2023 | 2023 | Q3 |
| Q2 2023 | $9,700,000 | +$453,000 | +4.9% | 30 Jun 2023 | 10-Q | 07 Aug 2023 | 2023 | Q2 |
| Q1 2023 | $10,916,000 | +$3,023,000 | +38% | 31 Mar 2023 | 10-Q | 08 May 2023 | 2023 | Q1 |
| Q4 2022 | $8,326,000 | -$799,000 | -8.8% | 31 Dec 2022 | 10-K | 28 Feb 2024 | 2023 | FY |
| Q3 2022 | $8,569,000 | -$3,856,000 | -31% | 30 Sep 2022 | 10-Q | 07 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $9,247,000 | -$617,000 | -6.3% | 30 Jun 2022 | 10-Q | 08 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $7,893,000 | -$6,398,000 | -45% | 31 Mar 2022 | 10-Q | 09 May 2022 | 2022 | Q1 |
| Q4 2021 | $9,125,000 | -$4,333,000 | -32% | 31 Dec 2021 | 10-K | 06 Mar 2023 | 2022 | FY |
| Q3 2021 | $12,425,000 | -$2,761,000 | -18% | 30 Sep 2021 | 10-Q | 09 Nov 2021 | 2021 | Q3 |
| Q2 2021 | $9,864,000 | 30 Jun 2021 | 10-Q | 09 Aug 2021 | 2021 | Q2 | ||
| Q1 2021 | $14,291,000 | 31 Mar 2021 | 10-Q | 13 May 2021 | 2021 | Q1 | ||
| Q4 2020 | $13,458,000 | +$10,343,000 | +332% | 31 Dec 2020 | 10-K | 28 Feb 2022 | 2021 | FY |
| Q3 2020 | $15,186,000 | 30 Sep 2020 | 10-Q | 13 Nov 2020 | 2020 | Q3 | ||
| Q4 2019 | $3,115,000 | 31 Dec 2019 | 10-K | 12 Mar 2021 | 2020 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.